Ronald J. Graf, MD joined MultiCare Health System in December of 2009. He has been conducting research in Pierce County since 1978. Dr. Graf is a highly regarded endocrinologist and researcher and he has an excellent rapport with his patients.
Because of his success as a Principal Investigator, sponsors often request his site for their clinical trials. Two of our MultiCare Internal Medicine Specialists have joined Dr. Graf as co-investigators. Dr. Graf has conducted clinical trials in a wide variety of therapeutic areas including:
Our Endocrinology and General Medicine Investigators include:
Ronald J. Graf, MD, FAACE (Principal Investigator)
Daniel C. Ginsberg, MD, FACP (Co-Investigator)
Bradley J. Schmitz, MD (Co-Investigator)
Kletter, B. Gadi, MD IPrincipal Investigator, Pediatric)
Study Number: D169AC00001 - A study to Evaluate the Effect of Dapagilflozin on Renal Outcomes and CArdiovascualr Mortality in Patients with Chronic Kidney Disease.
Principal Investigator(s): Ronald Graf, MD
Study Coordinator: Denise Quinn, [email protected], 253-301-6991
Study Number: GL-GLAT1-3001 - Open-label, randomized, multicenter, phase 3 study to compare the immunogenicity, efficacy, and safety of Gan & Lee Pharmaceuticals insulin glargine injection to Lantus (insulin glargine injection) in adult subjects with Type 1 diabetes mellitus.
Study Number: CNTO148DML2001 - A Study of SIMPSONI to arrest beta-cell loss in Type 1 diabetes.
Study Number: H9X-MC-GBGC - A randomized, double-blind study with an open-label extension comparing the effect of once-weekly Dulaglutide with placebo in pediatric patients with Type 2 diabetes mellitus.
Study Number: D1680C00019 - A 24-week, multicenter, randomized, placebo-controlled, double-blind, parallel group, phase 3 trial with a 28-week safety extension period evaluating the safety and efficacy of Dapagliflozin 5 and 10 mg, and Saxagliptin 2.5 and 5 mg in pediatric patients with Type 2 diabetes mellitus who are between 10 and below 18 years of age.
Study Number: JNJ-28431754DIA3018 - A randomized, multicenter, double-blind, parallel-group, placebo-controlled study to investigate the efficacy and safety of Canagliflozin in children and adolescents (10 years and older to <18 years) with Type 2 diabetes mellitus.
Study Number: A phase 3, multicenter, double-blind, randomized, placebo-controlled clinical trial to evaluate the safety and efficacy of Sitagliptin in pediatric patients with Type 2 diabetes mellitus with inadequate glycemic control.
Study Number: A phase 3 multicenter, double-blind, randomized, placebo-controlled clinical trial to evaluate the safety and efficacy of MK-0431A XR (a fixed-dose combination table of Sitagliptin and extended-release Metformin) in pediatric patients with Type 2 diabetes mellitus with inadequate glycemic control on Metformin therapy (alone or in combination with insulin).
Study Number: SYR-322-309 - A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of Alogliptin compared with placebo in pediatric subjects with Type 2 diabetes mellitus.
Study Number: TransCon hGH CT-301 - A multicenter, phase 3, randomized, open-label, active-controlled, parallel-group trial investigating the safety, tolerability, and efficacy of TransCon hGH administered once a week versus standard daily hGH replacement therapy over 52 weeks prepubertal children with growth hormone deficiency (GHD).
Study Number: CP-4-006 - A phase 3, open-label, randomized, multicenter, 12 months, efficacy and safety study of weekly MOD-4023 compared to daily Genotropin therapy in prepubertal children with growth hormone deficiency.